Product Information
GLIPIZIDE-METFORMIN 2.5-250 MG is a generic product labeled by Chartwell RX LLC, priced at $0.2418 per EA under NDC 62135073160. Its NADAC has been published 134 times since Mar 13, 2024.
FDA first approved this application on Jun 23, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5; 250 mg/1; mg/1
Manufacturer
Chartwell RX LLCNDC
62135073160
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GLIPIZIDE; METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078728FDA Approved
6/23/2010
TE Code
AB
On Market Since
6/29/2010
Pharmacological Classes
Price Statistics
The NADAC for GLIPIZIDE-METFORMIN 2.5-250 MG has been published 134 times since Mar 13, 2024, and over the history we have for it it has declined 2.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2418 per EA |
|---|---|
| All-time high | $0.3003 (Jul 15, 2026) |
| All-time low | $0.1748 (Nov 19, 2025) |
| 52-week high | $0.3003 |
| 52-week low | $0.1748 |
| Median price | $0.2451 |
| Average price | $0.2417 |
| Largest weekly change | +16.8% (Nov 20, 2024) |
| Weeks tracked | 134 |
| Tracking since | Mar 13, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Glipizide and metformin hcl market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glipizide and metformin hcl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLIPIZIDE-METFORMIN 2.5-250 MG?
The current National Average Drug Acquisition Cost (NADAC) for GLIPIZIDE-METFORMIN 2.5-250 MG, manufactured by Chartwell RX LLC, is $0.2418 per EA (NDC 62135073160), effective Sep 30, 2026.
How has the price of GLIPIZIDE-METFORMIN 2.5-250 MG changed over time?
Over the history we have for it, the NADAC for GLIPIZIDE-METFORMIN 2.5-250 MG has declined 2.5%. It has been tracked across 134 weekly CMS publications since Mar 13, 2024.
What are the highest and lowest recorded NADAC prices for GLIPIZIDE-METFORMIN 2.5-250 MG?
Since Mar 13, 2024, the NADAC for GLIPIZIDE-METFORMIN 2.5-250 MG has ranged from a low of $0.1748 (Nov 19, 2025) to a high of $0.3003 (Jul 15, 2026), with a median of $0.2451 per EA.
Are there cheaper alternatives to GLIPIZIDE-METFORMIN 2.5-250 MG?
No other NADAC-published product currently shares the active ingredient and strength of GLIPIZIDE-METFORMIN 2.5-250 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GLIPIZIDE-METFORMIN 2.5-250 MG?
GLIPIZIDE-METFORMIN 2.5-250 MG (NDC 62135073160) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.